Neurology Specific Literature Search   
 
[home][thesaurus]
    

Differential
(Click to cross reference)
acrocyanosis
advances in neurology
adverse drug reaction
Aicardi-Goutieres syndrome
alemtuzumab
aorta, sheathing
aortitis
arthralgia
ataxia
ataxic gait
atypical
azathioprine
basal ganglia, calcification of
BRAF protooncogene
brain atrophy
brainstem, lesion of
calcification, intracranial
CAT scan, abdomen
CAT scan, abnormal
CAT scan, chest
cerebellar lesion
cerebral cortical atrophy
cerebrospinal fluid, abnormal
chilbran skin lesions
children
chorea
chromosome 3
Churg-Strauss syndrome
Clinical Pathologic Conference(C.P.C.)
cold intolerance
complications
cop 1
cryoglobulinemia
cyclophosphamide
cyclosporine
cyst
cyst, parenchymal
cytokines
daclizumab
dementia
dementia, treatment of
dentate nuclei, lesion of
developmental milestones, loss of
diabetes insipidus
diagnostic criteria
differential diagnosis
diplopia
disability, neurological
dystonia
dystonia, children
efficacy
encephalopathy
Erdheim-Chester disease
evidence-based research
eye movement, disorders of
familial
fatigue
feeding disorder
fever
gadolinium
gene
gene mutation
genetic diagnosis, prenatal
genetic neurologic disorders
Guillain Barre syndrome
head lag
hepatitis
hepatitis C virus
histiocytosis
human T-lymphotropic virus type I(HTLV-I)
hyperpyrexia, CNS disorder causing
hypothalamus
hypothalamus, damage to
hypotonia
iatrogenic neurologic disorders
idiopathic thrombocytopenic purpura
imbalance
immunomodulation
immunosuppression
immunosuppressive agents
insomnia
intellectual deficit
interferon
interferon alpha
interferon beta 1-a
interferon beta 1-b
interferon, intraventricular
intrauterine
irritability
leukodystrophy
leukoencephalopathy
leukopenia
liver disease
liver function enzymes
long bone lesion
microcephaly
misdiagnosis
monoclonal antibodies
mononeuropathy multiplex
mortality
movement disorder
MRI
MRI, abnormal
MRI, contrast enhanced
MRI, serial
MRI, skull bone changes
multiple sclerosis
multiple sclerosis, relapsing
multiple sclerosis, treatment of
myelopathy
natalizumab
neurologic disease, diagnoses of
neuropathology
neuropathy
neuropathy, sensory
neuropathy, vasculitic, nonsystemic
neurotoxic
nonsteroidal anti-inflammatory drug
optic neuropathy
pain
pentoxifylline
pituitary stalk
pituitary stalk, lesion of
pituitary, lesion of
plasmapheresis
pleocytosis of cerebrospinal fluid
pons, lesion of
prenatal
prognosis
progressive multifocal leucoencephalopathy
psychomotor retardation
pyramidal tract dysfunction
radiation therapy, total body
retroperitoneal fibrosis
review article
risk-benefit assessment
sclerosis, bone
skin, biopsy
skin, lesions in neurologic disorders
somnolence
spastic diplegia
speech disorder, childhood
startle reaction
steroid therapy, CNS treatment and complications with
subacute sclerosing panencephalitis(S.S.P.E.)Dawson's disease
suprasellar lesion
T cell lymphocytes
treatment of neurologic disorder
tumor necrosis factor
tumor necrosis factor inhibitor
vasculitides
viral infection
walking frame
white matter disease
Showing articles 250 to 300 of 519 << Previous Next >>

Mangnetic Resonance Imaging Effects of Interferon Beta-1b in the BENEFIT Study: Integrated 2-Year Results
Arch Neurol 64:1292-1298, Barkhof,F.,et al, 2007

A 75-Year-Old Man With Cognitive Impairment and Gait Changes, Lewy Body Disease
Neurol 69:1183-1189, Lippa,C.F.,et al, 2007

Daclizumab Phase II Trial in Relapsing and Remitting Multiple Sclerosis
Neurol 69:785-789, Rose,J.W.,et al, 2007

Health-Related Quality of Life in Multiple Sclerosis: Effects of Natalizumab
Ann Neurol 62:335-346, Rudick,R.A.,et al, 2007

Neutralizing Antibodies to Interferon Beta: Assessment of Their Clinical and Radiographic Impact: An Evidence Report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 69:1552-1553, Sorenson,P.S. &Bertolotto,A., 2007

How Effective Are Disease-Modifying Drugs in Delaying Progression in Relapsing-Onset MS?
Neurol 69:1498-1507, Brown,M.G.,et al, 2007

Glycogen-Storage Disease Type II
eMedicine, May 2, Ibrahim,J. &McGovern,M., 2006

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
NEJM 354:899-910,965, Polman,C.H.,et al, 2006

Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy
NEJM 354:924-933,965, Yousry,T.A.,et al, 2006

IM Interferon B-1a Delays Definite Multiple Sclerosis 5 Years After a First Demyelinating Event
Neurol 66:678-684, CHAMPIONS Study Group, 2006

Clinicopath Conf, Diffuse Large B-Cell Lymphoma, EBV-Positive, with Immunosuppression
NEJM 354:1178-1184, Case 8-2006, 2006

The Parkinsons Complex: Parkinsonism Is Just the Tip of the Iceberg
Ann Neurol 59:591-596, Langston,J.W., 2006

Natalizumab: Immune Effects and Implications for Therapy
Ann Neurol 59:731-732, Hauser,S.L. &Weiner, H.L., 2006

Oral Contraceptives and Increased Headache Prevalence, The Head-HUNT Study
Neurol 66:349-353, Aegidius,K.,et al, 2006

Safety and Tolerability of Interferon Beta-1b in Pediatric Multiple Sclerosis
Neurol 66:472-476, Banwell,B.,et al, 2006

Emerging Monoclonal Antibody Therapies for Multiple Sclerosis
Neurologist 12:171-178, Cree,B., 2006

Progressive Multifocal Leukoencephalopathy Revisited: Has the Disease Outgrown Its Name?
Ann Neurol 60:162-173, Koralnik,I.J., 2006

Interferon beta-1a Treatment in Childhood and Juvenile-Onset Multiple Sclerosis
Neurol 67:511-513, Tenembaum,S.N. &Segura,M.J., 2006

Collaborative Analysis of a-Synuclein Gene Promotor Variability and Parkinson Disease
JAMA 296:661-670, Maraganore,D.M.,et al, 2006

Treatment With Interferon beta-1b Delays Conversion to Clinically Definite and McDonald MS in Patients With Clinically Isolated Syndromes
Neurol 67:1242-1249, Kappos,L.,et al, 2006

Infusion-Related Hypersensitivity Reactions During Natalizumab Treatment
Neurol 67:1717-1718, Phillips,J.T.,et al, 2006

Treatment of Early Onset Multiple Sclerosis With Subcutaneous Interferon Beta-1a
Neurol 64:888-890, 778, Pohl,D., et al, 2005

Thrombosis of the Cerebral VEins and Sinuses
NEJM 352:1791-1798, Stam,J., 2005

FDA Public Health advisory-Suspended Marketing of Tysabri (natalizumab)
www.fda.gov/cder/drug/advisory/natalizumab.htm.,(Feb 28), US Food and Drug Admin., 2005

Enhanced Benefit of Increasing Interferon Beta-1a Dose and Frequency in Relapsing Multiple Sclerosis
Arch Neurol 62:785-792, Schwid,S.R.,et al, 2005

Neutralizing Anti-IFN-B Antibodies
Neurol 65:6-8, Giovannoni,G.&Goodman,A., 2005

Life-Threatening Acute Pancreatitis Associated with Interferon Beta-1a Treatment in Multiple Sclerosis
Neurol 65:170-171, Midgard,R.,et al, 2005

Imaging of Cerebral Isolated Cortical Vein Thrombosis
AJR 184:1317-1319, Duncan,I.C.&Fourie,P.A., 2005

Polyneuropathy Associated with Interferon Beta Treatment in Patients with Multiple Sclerosis
Neurol 65:456-458, Ekstein,D.,et al, 2005

The Spectrum of Presentations of Venous Infarction Caused by Deep Cerebral Vein Thrombosis
Neurol 65:192-196, van den Bergh,W.M.,et al, 2005

Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis
NEJM 353:369-374,414,432, Kleinschemidt-DeMasters,B.K. &Tyler,K.L., 2005

Prothrombin 20210A and Oral Contraceptive Use as Risk Factors for Cerebral Venous Thrombosis
Cerebrovasc Dis 19:49-52, Gadelha,T.,et al, 2005

Cerebral Venous Thrombosis: Influence of Risk Factors and Imaging Findings on Prognosis
Clin Neurol Neurosurg 107:371-378, Appenzeller,S.,et al, 2005

Recent Use of Oral Contraceptives and the Risk of Multiple Sclerosis
Arch Neurol 62:1362-1365, Alonso,A.,et al, 2005

Pregnancy Outcomes During Treatment with Interferon Beta-1a in Patients with Multiple Sclerosis
Neurol 65:802-806, Sandberg-Wollheim,M.,et al, 2005

The Reproductive Effects of Beta Interferon Therapy in Pregnancy, A longitudinal Cohort
Neurol 65:807-811,788, Boskovic,R.,et al, 2005

Infliximab and Reactivation of Cerebral Toxoplasmosis
NEJM 353:1530-1531, Callegari,P.E., 2005

Efficacy of TNF a Blockade in Cyclophosphamide Resistant Neuro-Behet Disease
JNNP 76:1733-1735, Ribi,C.,et al, 2005

The New Antiepileptic Drugs, Clinical Applications
JAMA 291:615-620, LaRoche,S.M.&Helmers,S.L., 2004

Liver Injury Associated with the B-Interferons for MS
Neurol 62:628-631, Tremlett,H.L.,et al, 2004

Fatal Myositis Due to the Microsporidian Brachiola algerae, a Mosquito Pathogen
NEJM 351:42-47, Coyle,C.M.,et al, 2004

Clinical Implications of Benign Multiple Sclerosis: A 20-Year Population-Based Follow-Up Study
Ann Neurol 56:303-306, Pittock,S.J.,et al, 2004

Clinicopath Conf, Multiple-System Atrophy
NEJM 351:912-921, Case 27-2004, 2004

Salvage Therapy for Primary CNS Lymphoma with a Combination of Rituximab and Temozolomide
Neurol 63:901-903, Enting,R.H.,et al, 2004

Interferon Beta-1a for Brain Tissue Loss in Patients at Presentation with Syndromes Suggestive of Multiple Sclerosis: A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 364:1489-1496,1463, Filippi,M.,et al, 2004

Narcolepsy and Excessive Daytime Sleepiness
BMJ 329:724-728, Zeman,A.,et al, 2004

Interferon beta-1b in Secondary Progressive MS
Neurol 63:1779-1787,1768, Kappos,L.,et al, 2004

Interferon beta-1b in Secondary Progressive MS
Neurol 63:1788-1795,1768, The North American Study Group on Interferon beta-, 2004

Interferons in Relapsing Remitting Multiple Sclerosis: A Systematic Review
Lancet 361:545-552, Filippini,G.,et al, 2003

Bilateral Anterior Toxic Optic Neuropathy and the Use of Infliximab
BMJ 326:579, ten Tusscher,M.P.M.,et al, 2003



Showing articles 250 to 300 of 519 << Previous Next >>